Literature DB >> 12219832

A novel polyethylene depot device for the study of PLGA and P(FASA) microspheres in vitro and in vivo.

Maryellen Sandor1, Joshua Harris, Edith Mathiowitz.   

Abstract

Polymer microspheres (0.5-5.0 microm) are difficult to characterize in vivo because they degrade, migrate, and are endocytosed. A novel polyethylene mesh pouch containing microspheres allowed for retrieval of degraded polymeric products from rats without affecting the rate of degradation. Pouches containing poly(lactic-co-glycolic acid) (PLGA) or poly(fumaric-co-sebacic acid) (P(FASA)) microspheres were implanted intramuscularly, subcutaneously, and intraperitoneally and analyzed after 3, 7, 14, and 28 days. In vivo, subcutaneous or intraperitoneal implants experienced an immediate mass loss and a delayed decrease in molecular weight (Mw). Intramuscular implants behaved similarly to in vitro samples, decreasing in Mw immediately and lagging in mass loss. These results suggest that mass loss, which is usually dependent on Mw loss in vitro, may be directly due to enzymatic, rather than hydrolytic, degradation subcutaneously and intraperitoneally, while intramuscular implants appear to be mostly dependent on hydrolytic cleavage. This observation is further supported by histology. Additional experiments on pouches loaded with PLGA microspheres encapsulating osteoprotegerin, a protein drug used to prevent bone resorption, revealed that use of the device prevented the artifactual polymer compression inherent to microsphere centrifugation during release studies and allowed for the extraction of active protein from microspheres implanted for 3 days in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12219832     DOI: 10.1016/s0142-9612(02)00183-7

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  6 in total

1.  Towards more realistic in vitro release measurement techniques for biodegradable microparticles.

Authors:  D Klose; N Azaroual; F Siepmann; G Vermeersch; J Siepmann
Journal:  Pharm Res       Date:  2008-10-29       Impact factor: 4.200

2.  A nanoparticle depot formulation of 4-(N)-stearoyl gemcitabine shows a strong anti-tumour activity.

Authors:  Saijie Zhu; Xinran Li; Dharmika S P Lansakara-P; Amit Kumar; Zhengrong Cui
Journal:  J Pharm Pharmacol       Date:  2012-10-14       Impact factor: 3.765

3.  Design of estradiol loaded PLGA nanoparticulate formulations: a potential oral delivery system for hormone therapy.

Authors:  S Hariharan; V Bhardwaj; I Bala; J Sitterberg; U Bakowsky; M N V Ravi Kumar
Journal:  Pharm Res       Date:  2006-11-08       Impact factor: 4.200

4.  The PLGA nanoparticles for sustainable release of CGRP to ameliorate the inflammatory and vascular disorders in the lung of CGRP-deficient rats.

Authors:  Fang Wang; Yu Deng; Jieting Wang; Luying Yu; Fadian Ding; Wei Lian; Qicai Liu; Xinhua Lin
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

5.  Preparation and in vitro/in vivo evaluation of PLGA microspheres containing norquetiapine for long-acting injection.

Authors:  Chun-Woong Park; Hyo-Jung Lee; Dong-Won Oh; Ji-Hyun Kang; Chang-Soo Han; Dong-Wook Kim
Journal:  Drug Des Devel Ther       Date:  2018-04-05       Impact factor: 4.162

6.  Immunogenicity of pulsatile-release PLGA microspheres for single-injection vaccination.

Authors:  Rohiverth Guarecuco; Jennifer Lu; Kevin J McHugh; James J Norman; Lavanya S Thapa; Emily Lydon; Robert Langer; Ana Jaklenec
Journal:  Vaccine       Date:  2017-06-19       Impact factor: 3.641

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.